ID   NR1D1_MOUSE             Reviewed;         615 AA.
AC   Q3UV55; Q3UJJ1; Q62171; Q6EEZ6; Q922A5; Q9ESY4;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 1.
DT   07-APR-2021, entry version 150.
DE   RecName: Full=Nuclear receptor subfamily 1 group D member 1;
DE   AltName: Full=Rev-erbA-alpha;
DE   AltName: Full=V-erbA-related protein 1;
DE            Short=EAR-1;
GN   Name=Nr1d1; Synonyms=Ear1;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J, DBA/2J, and NOD; TISSUE=Bone, and Cerebellum;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-186.
RC   STRAIN=BALB/cJ; TISSUE=Liver;
RA   Sadek M.M., Chen Y., Elbrecht A.;
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-55.
RC   STRAIN=BALB/cJ; TISSUE=Skeletal muscle;
RA   Chomez P., Vennstrom B.;
RL   Submitted (APR-1995) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40.
RC   STRAIN=C57BL/6N;
RX   PubMed=15591021; DOI=10.1677/jme.1.01554;
RA   Triqueneaux G., Thenot S., Kakizawa T., Antoch M.P., Safi R.,
RA   Takahashi J.S., Delaunay F., Laudet V.;
RT   "The orphan receptor Rev-erbalpha gene is a target of the circadian clock
RT   pacemaker.";
RL   J. Mol. Endocrinol. 33:585-608(2004).
RN   [7]
RP   INTERACTION WITH C1D.
RX   PubMed=9405624; DOI=10.1073/pnas.94.26.14400;
RA   Zamir I., Dawson J., Lavinsky R.M., Glass C.K., Rosenfeld M.G., Lazar M.A.;
RT   "Cloning and characterization of a corepressor and potential component of
RT   the nuclear hormone receptor repression complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:14400-14405(1997).
RN   [8]
RP   INDUCTION.
RX   PubMed=14645221; DOI=10.1074/jbc.m311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the vascular
RT   clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=18565334; DOI=10.1053/j.gastro.2008.05.035;
RA   Duez H., van der Veen J.N., Duhem C., Pourcet B., Touvier T., Fontaine C.,
RA   Derudas B., Bauge E., Havinga R., Bloks V.W., Wolters H.,
RA   van der Sluijs F.H., Vennstrom B., Kuipers F., Staels B.;
RT   "Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha.";
RL   Gastroenterology 135:689-698(2008).
RN   [10]
RP   FUNCTION, TISSUE SPECIFICITY, AND PROTEASOMAL DEGRADATION.
RX   PubMed=18227153; DOI=10.1128/mcb.01608-07;
RA   Wang J., Lazar M.A.;
RT   "Bifunctional role of Rev-erbalpha in adipocyte differentiation.";
RL   Mol. Cell. Biol. 28:2213-2220(2008).
RN   [11]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18454201; DOI=10.1371/journal.pgen.1000023;
RA   Liu A.C., Tran H.G., Zhang E.E., Priest A.A., Welsh D.K., Kay S.A.;
RT   "Redundant function of REV-ERBalpha and beta and non-essential role for
RT   Bmal1 cycling in transcriptional regulation of intracellular circadian
RT   rhythms.";
RL   PLoS Genet. 4:E1000023-E1000023(2008).
RN   [12]
RP   FUNCTION.
RX   PubMed=19710360; DOI=10.1101/gad.1825809;
RA   Wu N., Yin L., Hanniman E.A., Joshi S., Lazar M.A.;
RT   "Negative feedback maintenance of heme homeostasis by its receptor, Rev-
RT   erbalpha.";
RL   Genes Dev. 23:2201-2209(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=19721697; DOI=10.1371/journal.pbio.1000181;
RA   Le Martelot G., Claudel T., Gatfield D., Schaad O., Kornmann B.,
RA   Lo Sasso G., Moschetta A., Schibler U.;
RT   "REV-ERBalpha participates in circadian SREBP signaling and bile acid
RT   homeostasis.";
RL   PLoS Biol. 7:E1000181-E1000181(2009).
RN   [14]
RP   FUNCTION IN CIRCADIAN RHYTHMS, INTERACTION WITH PER2, DISRUPTION PHENOTYPE,
RP   AND MUTAGENESIS OF LYS-456.
RX   PubMed=20159955; DOI=10.1101/gad.564110;
RA   Schmutz I., Ripperger J.A., Baeriswyl-Aebischer S., Albrecht U.;
RT   "The mammalian clock component PERIOD2 coordinates circadian output by
RT   interaction with nuclear receptors.";
RL   Genes Dev. 24:345-357(2010).
RN   [15]
RP   UBIQUITINATION AND PROTEASOMAL DEGRADATION.
RX   PubMed=20534529; DOI=10.1073/pnas.1000438107;
RA   Yin L., Joshi S., Wu N., Tong X., Lazar M.A.;
RT   "E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the
RT   circadian heme receptor Rev-erb alpha.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11614-11619(2010).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH OPHN1, PROTEASOMAL
RP   DEGRADATION, AND TISSUE SPECIFICITY.
RX   PubMed=21874017; DOI=10.1038/nn.2911;
RA   Valnegri P., Khelfaoui M., Dorseuil O., Bassani S., Lagneaux C.,
RA   Gianfelice A., Benfante R., Chelly J., Billuart P., Sala C., Passafaro M.;
RT   "A circadian clock in hippocampus is regulated by interaction between
RT   oligophrenin-1 and Rev-erbalpha.";
RL   Nat. Neurosci. 14:1293-1301(2011).
RN   [17]
RP   INTERACTION WITH PER2.
RX   PubMed=22170608; DOI=10.1038/nature10700;
RA   Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W.,
RA   Downes M., Evans R.M.;
RT   "Cryptochromes mediate rhythmic repression of the glucocorticoid
RT   receptor.";
RL   Nature 480:552-556(2011).
RN   [18]
RP   FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND DISRUPTION
RP   PHENOTYPE.
RX   PubMed=21408158; DOI=10.1371/journal.pone.0017494;
RA   Mollema N.J., Yuan Y., Jelcick A.S., Sachs A.J., von Alpen D.,
RA   Schorderet D., Escher P., Haider N.B.;
RT   "Nuclear receptor Rev-erb alpha (Nr1d1) functions in concert with Nr2e3 to
RT   regulate transcriptional networks in the retina.";
RL   PLoS ONE 6:E17494-E17494(2011).
RN   [19]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=22166979; DOI=10.1210/en.2011-1595;
RA   Vieira E., Marroqui L., Batista T.M., Caballero-Garrido E., Carneiro E.M.,
RA   Boschero A.C., Nadal A., Quesada I.;
RT   "The clock gene Rev-erbalpha regulates pancreatic beta-cell function:
RT   modulation by leptin and high-fat diet.";
RL   Endocrinology 153:592-601(2012).
RN   [20]
RP   FUNCTION.
RX   PubMed=22474260; DOI=10.1101/gad.186858.112;
RA   Bugge A., Feng D., Everett L.J., Briggs E.R., Mullican S.E., Wang F.,
RA   Jager J., Lazar M.A.;
RT   "Rev-erbalpha and Rev-erbbeta coordinately protect the circadian clock and
RT   normal metabolic function.";
RL   Genes Dev. 26:657-667(2012).
RN   [21]
RP   FUNCTION, INTERACTION WITH SP1, AND INDUCTION.
RX   PubMed=22549838; DOI=10.1038/ncomms1812;
RA   Negoro H., Kanematsu A., Doi M., Suadicani S.O., Matsuo M., Imamura M.,
RA   Okinami T., Nishikawa N., Oura T., Matsui S., Seo K., Tainaka M., Urabe S.,
RA   Kiyokage E., Todo T., Okamura H., Tabata Y., Ogawa O.;
RT   "Involvement of urinary bladder Connexin43 and the circadian clock in
RT   coordination of diurnal micturition rhythm.";
RL   Nat. Commun. 3:809-809(2012).
RN   [22]
RP   FUNCTION.
RX   PubMed=22184247; DOI=10.1073/pnas.1106750109;
RA   Gibbs J.E., Blaikley J., Beesley S., Matthews L., Simpson K.D., Boyce S.H.,
RA   Farrow S.N., Else K.J., Singh D., Ray D.W., Loudon A.S.;
RT   "The nuclear receptor REV-ERBalpha mediates circadian regulation of innate
RT   immunity through selective regulation of inflammatory cytokines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:582-587(2012).
RN   [23]
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=23531614; DOI=10.1152/ajpendo.00512.2012;
RA   Barclay J.L., Shostak A., Leliavski A., Tsang A.H., Johren O.,
RA   Muller-Fielitz H., Landgraf D., Naujokat N., van der Horst G.T., Oster H.;
RT   "High-fat diet-induced hyperinsulinemia and tissue-specific insulin
RT   resistance in Cry-deficient mice.";
RL   Am. J. Physiol. 304:E1053-E1063(2013).
RN   [24]
RP   INTERACTION WITH CCAR2.
RX   PubMed=23398316; DOI=10.1042/bj20121085;
RA   Chini C.C., Escande C., Nin V., Chini E.N.;
RT   "DBC1 (Deleted in Breast Cancer 1) modulates the stability and function of
RT   the nuclear receptor Rev-erbalpha.";
RL   Biochem. J. 451:453-461(2013).
RN   [25]
RP   FUNCTION.
RX   PubMed=23201262; DOI=10.1016/j.febslet.2012.11.021;
RA   Negoro H., Okinami T., Kanematsu A., Imamura M., Tabata Y., Ogawa O.;
RT   "Role of Rev-erbalpha domains for transactivation of the connexin43
RT   promoter with Sp1.";
RL   FEBS Lett. 587:98-103(2013).
RN   [26]
RP   FUNCTION.
RX   PubMed=24030830; DOI=10.1074/jbc.m113.507038;
RA   Xiao J., Zhou Y., Lai H., Lei S., Chi L.H., Mo X.;
RT   "Transcription factor NF-Y is a functional regulator of the transcription
RT   of core clock gene Bmal1.";
RL   J. Biol. Chem. 288:31930-31936(2013).
RN   [27]
RP   FUNCTION.
RX   PubMed=23852339; DOI=10.1038/nm.3213;
RA   Woldt E., Sebti Y., Solt L.A., Duhem C., Lancel S., Eeckhoute J.,
RA   Hesselink M.K., Paquet C., Delhaye S., Shin Y., Kamenecka T.M., Schaart G.,
RA   Lefebvre P., Neviere R., Burris T.P., Schrauwen P., Staels B., Duez H.;
RT   "Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating
RT   mitochondrial biogenesis and autophagy.";
RL   Nat. Med. 19:1039-1046(2013).
RN   [28]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=24162845; DOI=10.1038/nature12642;
RA   Gerhart-Hines Z., Feng D., Emmett M.J., Everett L.J., Loro E., Briggs E.R.,
RA   Bugge A., Hou C., Ferrara C., Seale P., Pryma D.A., Khurana T.S.,
RA   Lazar M.A.;
RT   "The nuclear receptor Rev-erbalpha controls circadian thermogenic
RT   plasticity.";
RL   Nature 503:410-413(2013).
RN   [29]
RP   FUNCTION.
RX   PubMed=23728303; DOI=10.1038/nature12209;
RA   Lam M.T., Cho H., Lesch H.P., Gosselin D., Heinz S., Tanaka-Oishi Y.,
RA   Benner C., Kaikkonen M.U., Kim A.S., Kosaka M., Lee C.Y., Watt A.,
RA   Grossman T.R., Rosenfeld M.G., Evans R.M., Glass C.K.;
RT   "Rev-Erbs repress macrophage gene expression by inhibiting enhancer-
RT   directed transcription.";
RL   Nature 498:511-515(2013).
RN   [30]
RP   FUNCTION.
RX   PubMed=23936124; DOI=10.1371/journal.pone.0069939;
RA   Vieira E., Marroqui L., Figueroa A.L., Merino B., Fernandez-Ruiz R.,
RA   Nadal A., Burris T.P., Gomis R., Quesada I.;
RT   "Involvement of the clock gene Rev-erb alpha in the regulation of glucagon
RT   secretion in pancreatic alpha-cells.";
RL   PLoS ONE 8:E69939-E69939(2013).
RN   [31]
RP   INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24603368; DOI=10.1038/emm.2013.153;
RA   Noh J.Y., Han D.H., Kim M.H., Ko I.G., Kim S.E., Park N., Kyoung Choe H.,
RA   Kim K.H., Kim K., Kim C.J., Cho S.;
RT   "Presence of multiple peripheral circadian oscillators in the tissues
RT   controlling voiding function in mice.";
RL   Exp. Mol. Med. 46:E81-E81(2014).
RN   [32]
RP   FUNCTION.
RX   PubMed=24794873; DOI=10.1074/jbc.m114.569723;
RA   Aninye I.O., Matsumoto S., Sidhaye A.R., Wondisford F.E.;
RT   "Circadian regulation of Tshb gene expression by Rev-Erbalpha (NR1D1) and
RT   nuclear corepressor 1 (NCOR1).";
RL   J. Biol. Chem. 289:17070-17077(2014).
RN   [33]
RP   INTERACTION WITH NR0B2.
RX   PubMed=25212631; DOI=10.1002/hep.27437;
RA   Lee S.M., Zhang Y., Tsuchiya H., Smalling R., Jetten A.M., Wang L.;
RT   "Small heterodimer partner/neuronal PAS domain protein 2 axis regulates the
RT   oscillation of liver lipid metabolism.";
RL   Hepatology 61:497-505(2015).
RN   [34]
RP   UBIQUITINATION, PROTEASOMAL DEGRADATION, INTERACTION WITH FBXW7 AND CDK1,
RP   PHOSPHORYLATION AT THR-275, AND MUTAGENESIS OF THR-275 AND SER-279.
RX   PubMed=27238018; DOI=10.1016/j.cell.2016.05.012;
RA   Zhao X., Hirota T., Han X., Cho H., Chong L.W., Lamia K., Liu S.,
RA   Atkins A.R., Banayo E., Liddle C., Yu R.T., Yates J.R. III, Kay S.A.,
RA   Downes M., Evans R.M.;
RT   "Circadian amplitude regulation via FBXW7-targeted REV-ERBalpha
RT   degradation.";
RL   Cell 165:1644-1657(2016).
RN   [35]
RP   FUNCTION, INTERACTION WITH HSP90AA1 AND HSP90AB1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=27686098; DOI=10.1242/jcs.190959;
RA   Okabe T., Chavan R., Fonseca Costa S.S., Brenna A., Ripperger J.A.,
RA   Albrecht U.;
RT   "REV-ERBalpha influences the stability and nuclear localization of the
RT   glucocorticoid receptor.";
RL   J. Cell Sci. 129:4143-4154(2016).
RN   [36]
RP   LYSOSOME-MEDIATED DEGRADATION.
RX   PubMed=29937374; DOI=10.1016/j.cmet.2018.05.023;
RA   Toledo M., Batista-Gonzalez A., Merheb E., Aoun M.L., Tarabra E., Feng D.,
RA   Sarparanta J., Merlo P., Botre F., Schwartz G.J., Pessin J.E., Singh R.;
RT   "Autophagy regulates the liver clock and glucose metabolism by degrading
RT   CRY1.";
RL   Cell Metab. 28:268-281(2018).
RN   [37]
RP   FUNCTION, AND INTERACTION WITH NFIL3.
RX   PubMed=29653076; DOI=10.1016/j.bcp.2018.04.005;
RA   Zhao M., Zhang T., Yu F., Guo L., Wu B.;
RT   "E4bp4 regulates carboxylesterase 2 enzymes through repression of the
RT   nuclear receptor Rev-erbalpha in mice.";
RL   Biochem. Pharmacol. 152:293-301(2018).
RN   [38]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION BY CKSN1E.
RX   PubMed=29508494; DOI=10.1111/gtc.12571;
RA   Ohba Y., Tei H.;
RT   "Phosphorylation of N-terminal regions of REV-ERBs regulates their
RT   intracellular localization.";
RL   Genes Cells 23:285-293(2018).
RN   [39]
RP   FUNCTION.
RX   PubMed=30096135; DOI=10.1371/journal.pbio.2005886;
RA   Dyar K.A., Hubert M.J., Mir A.A., Ciciliot S., Lutter D., Greulich F.,
RA   Quagliarini F., Kleinert M., Fischer K., Eichmann T.O., Wright L.E.,
RA   Pena Paz M.I., Casarin A., Pertegato V., Romanello V., Albiero M.,
RA   Mazzucco S., Rizzuto R., Salviati L., Biolo G., Blaauw B., Schiaffino S.,
RA   Uhlenhaut N.H.;
RT   "Transcriptional programming of lipid and amino acid metabolism by the
RT   skeletal muscle circadian clock.";
RL   PLoS Biol. 16:E2005886-E2005886(2018).
RN   [40]
RP   FUNCTION, TISSUE SPECIFICITY, DISRUPTION PHENOTYPE, UBIQUITINATION,
RP   PROTEASOMAL DEGRADATION, AND SUMOYLATION.
RX   PubMed=29533925; DOI=10.1172/jci93910;
RA   Pariollaud M., Gibbs J.E., Hopwood T.W., Brown S., Begley N., Vonslow R.,
RA   Poolman T., Guo B., Saer B., Jones D.H., Tellam J.P., Bresciani S.,
RA   Tomkinson N.C., Wojno-Picon J., Cooper A.W., Daniels D.A., Trump R.P.,
RA   Grant D., Zuercher W., Willson T.M., MacDonald A.S., Bolognese B.,
RA   Podolin P.L., Sanchez Y., Loudon A.S., Ray D.W.;
RT   "Circadian clock component REV-ERBalpha controls homeostatic regulation of
RT   pulmonary inflammation.";
RL   J. Clin. Invest. 128:2281-2296(2018).
RN   [41]
RP   FUNCTION, AND INTERACTION WITH NR0B2.
RX   PubMed=30555544; DOI=10.7150/thno.28676;
RA   Zhang T., Yu F., Guo L., Chen M., Yuan X., Wu B.;
RT   "Small heterodimer partner regulates circadian cytochromes p450 and drug-
RT   induced hepatotoxicity.";
RL   Theranostics 8:5246-5258(2018).
RN   [42]
RP   HEME-BINDING, AND FUNCTION.
RX   PubMed=31748741; DOI=10.1038/s41586-019-1774-2;
RA   Galmozzi A., Kok B.P., Kim A.S., Montenegro-Burke J.R., Lee J.Y.,
RA   Spreafico R., Mosure S., Albert V., Cintron-Colon R., Godio C., Webb W.R.,
RA   Conti B., Solt L.A., Kojetin D., Parker C.G., Peluso J.J., Pru J.K.,
RA   Siuzdak G., Cravatt B.F., Saez E.;
RT   "PGRMC2 is an intracellular haem chaperone critical for adipocyte
RT   function.";
RL   Nature 576:138-142(2019).
RN   [43]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=30792350; DOI=10.1073/pnas.1812405116;
RA   Griffin P., Dimitry J.M., Sheehan P.W., Lananna B.V., Guo C.,
RA   Robinette M.L., Hayes M.E., Cedeno M.R., Nadarajah C.J., Ezerskiy L.A.,
RA   Colonna M., Zhang J., Bauer A.Q., Burris T.P., Musiek E.S.;
RT   "Circadian clock protein Rev-erbalpha regulates neuroinflammation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:5102-5107(2019).
CC   -!- FUNCTION: Transcriptional repressor which coordinates circadian rhythm
CC       and metabolic pathways in a heme-dependent manner. Integral component
CC       of the complex transcription machinery that governs circadian
CC       rhythmicity and forms a critical negative limb of the circadian clock
CC       by directly repressing the expression of core clock components
CC       ARTNL/BMAL1, CLOCK and CRY1. Also regulates genes involved in metabolic
CC       functions, including lipid and bile acid metabolism, adipogenesis,
CC       gluconeogenesis and the macrophage inflammatory response. Acts as a
CC       receptor for heme which stimulates its interaction with the NCOR1/HDAC3
CC       corepressor complex, enhancing transcriptional repression. Recognizes
CC       two classes of DNA response elements within the promoter of its target
CC       genes and can bind to DNA as either monomers or homodimers, depending
CC       on the nature of the response element. Binds as a monomer to a response
CC       element composed of the consensus half-site motif 5'-[A/G]GGTCA-3'
CC       preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a
CC       direct repeat of the core motif spaced by two nucleotides (RevDR-2).
CC       Acts as a potent competitive repressor of ROR alpha (RORA) function and
CC       regulates the levels of its ligand heme by repressing the expression of
CC       PPARGC1A, a potent inducer of heme synthesis. Regulates lipid
CC       metabolism by repressing the expression of APOC3 and by influencing the
CC       activity of sterol response element binding proteins (SREBPs);
CC       represses INSIG2 which interferes with the proteolytic activation of
CC       SREBPs which in turn govern the rhythmic expression of enzymes with key
CC       functions in sterol and fatty acid synthesis. Regulates gluconeogenesis
CC       via repression of G6PC1 and PEPCK and adipocyte differentiation via
CC       repression of PPARG. Regulates glucagon release in pancreatic alpha-
CC       cells via the AMPK-NAMPT-SIRT1 pathway and the proliferation, glucose-
CC       induced insulin secretion and expression of key lipogenic genes in
CC       pancreatic-beta cells. Positively regulates bile acid synthesis by
CC       increasing hepatic expression of CYP7A1 via repression of NR0B2 and
CC       NFIL3 which are negative regulators of CYP7A1. Modulates skeletal
CC       muscle oxidative capacity by regulating mitochondrial biogenesis and
CC       autophagy; controls mitochondrial biogenesis and respiration by
CC       interfering with the STK11-PRKAA1/2-SIRT1-PPARGC1A signaling pathway.
CC       Represses the expression of SERPINE1/PAI1, an important modulator of
CC       cardiovascular disease and the expression of inflammatory cytokines and
CC       chemokines in macrophages. Represses gene expression at a distance in
CC       macrophages by inhibiting the transcription of enhancer-derived RNAs
CC       (eRNAs). Plays a role in the circadian regulation of body temperature
CC       and negatively regulates thermogenic transcriptional programs in brown
CC       adipose tissue (BAT); imposes a circadian oscillation in BAT activity,
CC       increasing body temperature when awake and depressing thermogenesis
CC       during sleep. In concert with NR2E3, regulates transcriptional networks
CC       critical for photoreceptor development and function. In addition to its
CC       activity as a repressor, can also act as a transcriptional activator.
CC       In the ovarian granulosa cells acts as a transcriptional activator of
CC       STAR which plays a role in steroid biosynthesis. In collaboration with
CC       SP1, activates GJA1 transcription in a heme-independent manner.
CC       Represses the transcription of CYP2B10, CYP4A10 and CYP4A14
CC       (PubMed:30555544). Represses the transcription of CES2
CC       (PubMed:29653076). Represses and regulates the circadian expression of
CC       TSHB in a NCOR1-dependent manner (PubMed:24794873). Negatively
CC       regulates the protein stability of NR3C1 and influences the time-
CC       dependent subcellular distribution of NR3C1, thereby affecting its
CC       transcriptional regulatory activity (PubMed:27686098). Plays a critical
CC       role in the circadian control of neutrophilic inflammation in the lung;
CC       under resting, non-stress conditions, acts as a rhythmic repressor to
CC       limit inflammatory activity whereas in the presence of inflammatory
CC       triggers undergoes ubiquitin-mediated degradation thereby relieving
CC       inhibition of the inflammatory response (PubMed:29533925). Plays a key
CC       role in the circadian regulation of microglial activation and
CC       neuroinflammation; suppresses microglial activation through the NF-
CC       kappaB pathway in the central nervous system (PubMed:30792350). Plays a
CC       role in the regulation of the diurnal rhythms of lipid and protein
CC       metabolism in the skeletal muscle via transcriptional repression of
CC       genes controlling lipid and amino acid metabolism in the muscle
CC       (PubMed:30096135). {ECO:0000269|PubMed:18227153,
CC       ECO:0000269|PubMed:18454201, ECO:0000269|PubMed:18565334,
CC       ECO:0000269|PubMed:19710360, ECO:0000269|PubMed:19721697,
CC       ECO:0000269|PubMed:20159955, ECO:0000269|PubMed:21408158,
CC       ECO:0000269|PubMed:21874017, ECO:0000269|PubMed:22166979,
CC       ECO:0000269|PubMed:22184247, ECO:0000269|PubMed:22474260,
CC       ECO:0000269|PubMed:22549838, ECO:0000269|PubMed:23201262,
CC       ECO:0000269|PubMed:23728303, ECO:0000269|PubMed:23852339,
CC       ECO:0000269|PubMed:23936124, ECO:0000269|PubMed:24030830,
CC       ECO:0000269|PubMed:24162845, ECO:0000269|PubMed:24794873,
CC       ECO:0000269|PubMed:27686098, ECO:0000269|PubMed:29533925,
CC       ECO:0000269|PubMed:29653076, ECO:0000269|PubMed:30096135,
CC       ECO:0000269|PubMed:30555544, ECO:0000269|PubMed:30792350,
CC       ECO:0000269|PubMed:31748741}.
CC   -!- SUBUNIT: Binds DNA as a monomer or a homodimer (By similarity).
CC       Interacts with NR2E3 and ZNHIT1 (By similarity). Interacts with C1D
CC       (PubMed:9405624). Interacts with SP1 (PubMed:22549838). Interacts with
CC       OPHN1 (via C-terminus) (PubMed:21874017). Interacts with PER2; the
CC       interaction associates PER2 to ARNTL promoter region (PubMed:20159955,
CC       PubMed:22170608). Interacts with CRY1 (By similarity). Interacts with
CC       CCAR2 (PubMed:23398316). Interacts with SIAH2 (By similarity).
CC       Interacts with FBXW7 and CDK1 (PubMed:27238018). Interacts with HUWE1
CC       (By similarity). Interacts with NR0B2 (PubMed:25212631,
CC       PubMed:30555544). Interacts with NFIL3 (PubMed:29653076). Interacts
CC       (via domain NR LBD) with HSP90AA1 and HSP90AB1 (PubMed:27686098).
CC       {ECO:0000250|UniProtKB:P20393, ECO:0000269|PubMed:20159955,
CC       ECO:0000269|PubMed:21874017, ECO:0000269|PubMed:22170608,
CC       ECO:0000269|PubMed:22549838, ECO:0000269|PubMed:23398316,
CC       ECO:0000269|PubMed:25212631, ECO:0000269|PubMed:27238018,
CC       ECO:0000269|PubMed:27686098, ECO:0000269|PubMed:29653076,
CC       ECO:0000269|PubMed:30555544, ECO:0000269|PubMed:9405624}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407,
CC       ECO:0000269|PubMed:21874017, ECO:0000269|PubMed:27686098,
CC       ECO:0000269|PubMed:29508494}. Cytoplasm {ECO:0000269|PubMed:21874017,
CC       ECO:0000269|PubMed:27686098, ECO:0000269|PubMed:29508494}. Cell
CC       projection, dendrite {ECO:0000269|PubMed:21874017}. Cell projection,
CC       dendritic spine {ECO:0000269|PubMed:21874017}. Note=Localizes to the
CC       cytoplasm, dendrites and dendritic spine in the presence of OPHN1
CC       (PubMed:21874017). Localizes predominantly to the nucleus at ZT8
CC       whereas it is cytoplasmic at ZT20 (PubMed:27686098). Phosphorylation by
CC       CSNK1E enhances its cytoplasmic localization (PubMed:29508494).
CC       {ECO:0000269|PubMed:21874017, ECO:0000269|PubMed:27686098,
CC       ECO:0000269|PubMed:29508494}.
CC   -!- TISSUE SPECIFICITY: Expressed during adipocyte differentiation (at
CC       protein level). Expressed in skeletal muscle, bladder, lumbar spinal
CC       cord, pancreatic islets and hypothalamus. Expressed in developing and
CC       adult retina. In the adult retina, predominantly expressed in the outer
CC       nuclear layer, where rod and cone cells reside, and also localized to
CC       the ganglion cell layer. Expressed in a circadian manner in the liver
CC       (PubMed:27686098). Expressed in a circadian manner in the lung with a
CC       peak between ZT8 and ZT12 (PubMed:29533925).
CC       {ECO:0000269|PubMed:18227153, ECO:0000269|PubMed:18454201,
CC       ECO:0000269|PubMed:21408158, ECO:0000269|PubMed:21874017,
CC       ECO:0000269|PubMed:22166979, ECO:0000269|PubMed:23531614,
CC       ECO:0000269|PubMed:24603368, ECO:0000269|PubMed:27686098,
CC       ECO:0000269|PubMed:29533925}.
CC   -!- DEVELOPMENTAL STAGE: During development at embryonic day 18.5 dpc,
CC       expressed in the outer neuroblastic layer of the retina where
CC       developing postmitotic photoreceptors and retinal progenitors reside
CC       (at protein level). {ECO:0000269|PubMed:21408158}.
CC   -!- INDUCTION: Expression oscillates diurnally in the suprachiasmatic
CC       nucleus (SCN) of the hypothalamus as well as in peripheral tissues. In
CC       bladder smooth muscle cells, pancreas and lumbar spinal cord, exhibits
CC       night/day variations with a peak time at circadian time (CT) 4-12 and a
CC       trough at CT16-24. {ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:22549838, ECO:0000269|PubMed:23531614,
CC       ECO:0000269|PubMed:24603368}.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain, a
CC       DNA-binding domain and a C-terminal ligand-binding domain.
CC   -!- PTM: Ubiquitinated, leading to its proteasomal degradation
CC       (PubMed:20534529). Ubiquitinated by the SCF(FBXW7) complex when
CC       phosphorylated by CDK1 leading to its proteasomal degradation
CC       (PubMed:27238018). Ubiquitinated by SIAH2; leading to its proteasomal
CC       degradation (By similarity). Rapidly ubiquitinated in response to
CC       inflammatory triggers and sumoylation is a prerequisite to its
CC       ubiquitination (PubMed:29533925). {ECO:0000250|UniProtKB:P20393,
CC       ECO:0000269|PubMed:20534529, ECO:0000269|PubMed:27238018,
CC       ECO:0000269|PubMed:29533925}.
CC   -!- PTM: Sumoylated by UBE2I, desumoylated by SENP1, and sumoylation is a
CC       prerequisite to its ubiquitination. {ECO:0000269|PubMed:29533925}.
CC   -!- PTM: Phosphorylated by CSNK1E; phosphorylation enhances its cytoplasmic
CC       localization. {ECO:0000269|PubMed:29508494}.
CC   -!- PTM: Undergoes lysosome-mediated degradation in a time-dependent manner
CC       in the liver. {ECO:0000269|PubMed:29937374}.
CC   -!- DISRUPTION PHENOTYPE: Mice display increased cold tolerance, higher
CC       oxygen consumption rates, enhanced brown adipose tissue metabolic
CC       capacity, maintenance of higher body temperature throughout the light
CC       phase and increased glucose uptake only during the day. They also show
CC       retinal abnormalities such as pan-retinal spotting and decreased
CC       response to light and decreased bile acid accumulation. Double knockout
CC       for NR1D1 and PER2 show a significantly shorter period length compared
CC       with wild type or single knockouts for both genes. 50% of double
CC       knockouts animals show a stable circadian throughout at least 5 weeks
CC       in constant darkness. The other 50% of animals lose their circadian
CC       rhythmicity when held in constant darkness for an average of 21 days.
CC       Animals have blunted steady-state levels of glycogen in the liver in
CC       spite of normal patterns of food consumption. Mice show exaggerated
CC       pulmonary inflammatory responses (PubMed:29533925). Mice display
CC       enhanced spontaneous hippocampal microglial and astrocyte activation,
CC       increased microglial NF-kappaB signaling and exacerbated LPS-induced
CC       neuroinflammation in the hippocampus (PubMed:30792350). Conditional
CC       knockout of both NR1D1 and NR1D2 in bronchiolar epithelial cells
CC       abolished diurnal rhythmicity of PER2 in the bronchioles and increased
CC       inflammatory responses and chemokine activation (PubMed:29533925).
CC       {ECO:0000269|PubMed:20159955, ECO:0000269|PubMed:21408158,
CC       ECO:0000269|PubMed:24162845, ECO:0000269|PubMed:29533925,
CC       ECO:0000269|PubMed:30792350}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR1
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK137398; BAE23342.1; -; mRNA.
DR   EMBL; AK137582; BAE23418.1; -; mRNA.
DR   EMBL; AK146430; BAE27164.1; -; mRNA.
DR   EMBL; AK154931; BAE32932.1; -; mRNA.
DR   EMBL; AK155597; BAE33339.1; -; mRNA.
DR   EMBL; AL590963; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008989; AAH08989.1; -; mRNA.
DR   EMBL; AF291821; AAG01345.1; -; mRNA.
DR   EMBL; X86010; CAA59997.1; -; mRNA.
DR   EMBL; AY336125; AAS48348.1; -; Genomic_DNA.
DR   CCDS; CCDS25363.1; -.
DR   PIR; S52813; S52813.
DR   RefSeq; NP_663409.2; NM_145434.4.
DR   SMR; Q3UV55; -.
DR   BioGRID; 229856; 2.
DR   DIP; DIP-59440N; -.
DR   IntAct; Q3UV55; 1.
DR   STRING; 10090.ENSMUSP00000069505; -.
DR   iPTMnet; Q3UV55; -.
DR   PhosphoSitePlus; Q3UV55; -.
DR   MaxQB; Q3UV55; -.
DR   PaxDb; Q3UV55; -.
DR   PeptideAtlas; Q3UV55; -.
DR   PRIDE; Q3UV55; -.
DR   ProteomicsDB; 295516; -.
DR   Antibodypedia; 16433; 491 antibodies.
DR   Ensembl; ENSMUST00000064941; ENSMUSP00000069505; ENSMUSG00000020889.
DR   GeneID; 217166; -.
DR   KEGG; mmu:217166; -.
DR   UCSC; uc007lhh.2; mouse.
DR   CTD; 9572; -.
DR   MGI; MGI:2444210; Nr1d1.
DR   eggNOG; KOG4846; Eukaryota.
DR   GeneTree; ENSGT00940000160548; -.
DR   HOGENOM; CLU_007368_2_4_1; -.
DR   InParanoid; Q3UV55; -.
DR   OMA; YPPAWPP; -.
DR   OrthoDB; 1240230at2759; -.
DR   PhylomeDB; Q3UV55; -.
DR   TreeFam; TF328382; -.
DR   Reactome; R-MMU-383280; Nuclear Receptor transcription pathway.
DR   BioGRID-ORCS; 217166; 2 hits in 52 CRISPR screens.
DR   PRO; PR:Q3UV55; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; Q3UV55; protein.
DR   Bgee; ENSMUSG00000020889; Expressed in retinal neural layer and 184 other tissues.
DR   Genevisible; Q3UV55; MM.
DR   GO; GO:0000785; C:chromatin; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISO:MGI.
DR   GO; GO:0016604; C:nuclear body; ISO:MGI.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; ISO:MGI.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0020037; F:heme binding; ISO:MGI.
DR   GO; GO:0004879; F:nuclear receptor activity; IBA:GO_Central.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:MGI.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:MGI.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; ISO:MGI.
DR   GO; GO:0001222; F:transcription corepressor binding; ISS:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; ISO:MGI.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISO:MGI.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; IMP:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; IDA:MGI.
DR   GO; GO:0060086; P:circadian temperature homeostasis; IMP:UniProtKB.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0061889; P:negative regulation of astrocyte activation; IMP:UniProtKB.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; IMP:YuBioLab.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:UniProtKB.
DR   GO; GO:1903979; P:negative regulation of microglial cell activation; IMP:UniProtKB.
DR   GO; GO:0150079; P:negative regulation of neuroinflammatory response; IMP:UniProtKB.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; ISO:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0070859; P:positive regulation of bile acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0042753; P:positive regulation of circadian rhythm; ISO:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0010498; P:proteasomal protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IMP:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0042749; P:regulation of circadian sleep/wake cycle; IMP:UniProtKB.
DR   GO; GO:0045598; P:regulation of fat cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000489; P:regulation of hepatic stellate cell activation; ISO:MGI.
DR   GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IMP:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0061469; P:regulation of type B pancreatic cell proliferation; IMP:UniProtKB.
DR   GO; GO:0044321; P:response to leptin; IDA:UniProtKB.
DR   Gene3D; 1.10.565.10; -; 1.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR-like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Biological rhythms; Cell junction; Cell projection;
KW   Cytoplasm; Differentiation; DNA-binding; Heme; Iron; Metal-binding;
KW   Nucleus; Phosphoprotein; Receptor; Reference proteome; Repressor; Synapse;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..615
FT                   /note="Nuclear receptor subfamily 1 group D member 1"
FT                   /id="PRO_0000311182"
FT   DOMAIN          285..615
FT                   /note="NR LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT   DNA_BIND        130..206
FT                   /note="Nuclear receptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         133..153
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   ZN_FING         170..194
FT                   /note="NR C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT   REGION          1..129
FT                   /note="Modulating"
FT   REGION          1..70
FT                   /note="Required for phosphorylation by CSNK1E and
FT                   cytoplasmic localization"
FT                   /evidence="ECO:0000269|PubMed:30792350"
FT   REGION          49..285
FT                   /note="Crucial for activation of GJA1"
FT   COMPBIAS        79..94
FT                   /note="Poly-Ser"
FT   BINDING         419
FT                   /note="Heme"
FT                   /evidence="ECO:0000250"
FT   BINDING         603
FT                   /note="Heme"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         55
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P20393"
FT   MOD_RES         59
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:P20393"
FT   MOD_RES         192
FT                   /note="N6-acetyllysine; by KAT5"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         193
FT                   /note="N6-acetyllysine; by KAT5"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         275
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:27238018"
FT   MOD_RES         592
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P20393"
FT   MUTAGEN         275
FT                   /note="T->A: Loss of interaction with FBXW7 and loss of
FT                   CDK1-mediated phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:27238018"
FT   MUTAGEN         279
FT                   /note="S->A: Loss of interaction with FBXW7."
FT                   /evidence="ECO:0000269|PubMed:27238018"
FT   MUTAGEN         456
FT                   /note="K->A: Reduces interaction with PER2 by 60%."
FT                   /evidence="ECO:0000269|PubMed:20159955"
FT   CONFLICT        36
FT                   /note="S -> R (in Ref. 5; CAA59997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        40
FT                   /note="S -> R (in Ref. 5; CAA59997)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        84
FT                   /note="A -> T (in Ref. 1; BAE27164 and 3; AAH08989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        440
FT                   /note="F -> L (in Ref. 1; BAE27164)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   615 AA;  66802 MW;  FFEC491B616BB326 CRC64;
     MTTLDSNNNT GGVITYIGSS GSSPSRTSPE SLYSDSSNGS FQSLTQGCPT YFPPSPTGSL
     TQDPARSFGS APPSLSDDSS PSSASSSSSS SSSSFYNGSP PGSLQVAMED SSRVSPSKGT
     SNITKLNGMV LLCKVCGDVA SGFHYGVHAC EGCKGFFRRS IQQNIQYKRC LKNENCSIVR
     INRNRCQQCR FKKCLSVGMS RDAVRFGRIP KREKQRMLAE MQSAMNLANN QLSSLCPLET
     SPTPHPTSGS MGPSPPPAPA PTPLVGFSQF PQQLTPPRSP SPEPTMEDVI SQVARAHREI
     FTYAHDKLGT SPGNFNANHA SGSPSATTPH RWESQGCPSA PNDNNLLAAQ RHNEALNGLR
     QGPSSYPPTW PSGPTHHSCH QPNSNGHRLC PTHVYSAPEG EAPANSLRQG NTKNVLLACP
     MNMYPHGRSG RTVQEIWEDF SMSFTPAVRE VVEFAKHIPG FRDLSQHDQV TLLKAGTFEV
     LMVRFASLFN VKDQTVMFLS RTTYSLQELG AMGMGDLLNA MFDFSEKLNS LALTEEELGL
     FTAVVLVSAD RSGMENSASV EQLQETLLRA LRALVLKNRP SETSRFTKLL LKLPDLRTLN
     NMHSEKLLSF RVDAQ
//
